Cargando…

ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer

Adenosine-to-inosine RNA editing is a process mediated by adenosine deaminases that act on the RNA (ADAR) gene family. It has been discovered recently as an epigenetic modification dysregulated in human cancers. However, the clinical significance of RNA editing in patients with liver metastasis from...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Nanako, Shigeyasu, Kunitoshi, Umeda, Yuzo, Yano, Shuya, Takeda, Sho, Yoshida, Kazuhiro, Fuji, Tomokazu, Yoshida, Ryuichi, Yasui, Kazuya, Umeda, Hibiki, Takahashi, Toshiaki, Kondo, Yoshitaka, Kishimoto, Hiroyuki, Mori, Yoshiko, Teraishi, Fuminori, Yamamoto, Hideki, Michiue, Hiroyuki, Nakamura, Keiichiro, Tazawa, Hiroshi, Fujiwara, Toshiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902515/
https://www.ncbi.nlm.nih.gov/pubmed/36747029
http://dx.doi.org/10.1038/s41598-023-29397-z
_version_ 1784883279669755904
author Hata, Nanako
Shigeyasu, Kunitoshi
Umeda, Yuzo
Yano, Shuya
Takeda, Sho
Yoshida, Kazuhiro
Fuji, Tomokazu
Yoshida, Ryuichi
Yasui, Kazuya
Umeda, Hibiki
Takahashi, Toshiaki
Kondo, Yoshitaka
Kishimoto, Hiroyuki
Mori, Yoshiko
Teraishi, Fuminori
Yamamoto, Hideki
Michiue, Hiroyuki
Nakamura, Keiichiro
Tazawa, Hiroshi
Fujiwara, Toshiyoshi
author_facet Hata, Nanako
Shigeyasu, Kunitoshi
Umeda, Yuzo
Yano, Shuya
Takeda, Sho
Yoshida, Kazuhiro
Fuji, Tomokazu
Yoshida, Ryuichi
Yasui, Kazuya
Umeda, Hibiki
Takahashi, Toshiaki
Kondo, Yoshitaka
Kishimoto, Hiroyuki
Mori, Yoshiko
Teraishi, Fuminori
Yamamoto, Hideki
Michiue, Hiroyuki
Nakamura, Keiichiro
Tazawa, Hiroshi
Fujiwara, Toshiyoshi
author_sort Hata, Nanako
collection PubMed
description Adenosine-to-inosine RNA editing is a process mediated by adenosine deaminases that act on the RNA (ADAR) gene family. It has been discovered recently as an epigenetic modification dysregulated in human cancers. However, the clinical significance of RNA editing in patients with liver metastasis from colorectal cancer (CRC) remains unclear. The current study aimed to systematically and comprehensively investigate the significance of adenosine deaminase acting on RNA 1 (ADAR1) expression status in 83 liver metastatic tissue samples collected from 36 patients with CRC. The ADAR1 expression level was significantly elevated in liver metastatic tissue samples obtained from patients with right-sided, synchronous, or RAS mutant-type CRC. ADAR1-high liver metastasis was significantly correlated with remnant liver recurrence after hepatic metastasectomy. A high ADAR1 expression was a predictive factor of remnant liver recurrence (area under the curve = 0.72). Results showed that the ADAR1 expression level could be a clinically relevant predictive indicator of remnant liver recurrence. Patients with liver metastases who have a high ADAR1 expression requires adjuvant chemotherapy after hepatic metastasectomy.
format Online
Article
Text
id pubmed-9902515
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99025152023-02-08 ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer Hata, Nanako Shigeyasu, Kunitoshi Umeda, Yuzo Yano, Shuya Takeda, Sho Yoshida, Kazuhiro Fuji, Tomokazu Yoshida, Ryuichi Yasui, Kazuya Umeda, Hibiki Takahashi, Toshiaki Kondo, Yoshitaka Kishimoto, Hiroyuki Mori, Yoshiko Teraishi, Fuminori Yamamoto, Hideki Michiue, Hiroyuki Nakamura, Keiichiro Tazawa, Hiroshi Fujiwara, Toshiyoshi Sci Rep Article Adenosine-to-inosine RNA editing is a process mediated by adenosine deaminases that act on the RNA (ADAR) gene family. It has been discovered recently as an epigenetic modification dysregulated in human cancers. However, the clinical significance of RNA editing in patients with liver metastasis from colorectal cancer (CRC) remains unclear. The current study aimed to systematically and comprehensively investigate the significance of adenosine deaminase acting on RNA 1 (ADAR1) expression status in 83 liver metastatic tissue samples collected from 36 patients with CRC. The ADAR1 expression level was significantly elevated in liver metastatic tissue samples obtained from patients with right-sided, synchronous, or RAS mutant-type CRC. ADAR1-high liver metastasis was significantly correlated with remnant liver recurrence after hepatic metastasectomy. A high ADAR1 expression was a predictive factor of remnant liver recurrence (area under the curve = 0.72). Results showed that the ADAR1 expression level could be a clinically relevant predictive indicator of remnant liver recurrence. Patients with liver metastases who have a high ADAR1 expression requires adjuvant chemotherapy after hepatic metastasectomy. Nature Publishing Group UK 2023-02-06 /pmc/articles/PMC9902515/ /pubmed/36747029 http://dx.doi.org/10.1038/s41598-023-29397-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hata, Nanako
Shigeyasu, Kunitoshi
Umeda, Yuzo
Yano, Shuya
Takeda, Sho
Yoshida, Kazuhiro
Fuji, Tomokazu
Yoshida, Ryuichi
Yasui, Kazuya
Umeda, Hibiki
Takahashi, Toshiaki
Kondo, Yoshitaka
Kishimoto, Hiroyuki
Mori, Yoshiko
Teraishi, Fuminori
Yamamoto, Hideki
Michiue, Hiroyuki
Nakamura, Keiichiro
Tazawa, Hiroshi
Fujiwara, Toshiyoshi
ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer
title ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer
title_full ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer
title_fullStr ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer
title_full_unstemmed ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer
title_short ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer
title_sort adar1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902515/
https://www.ncbi.nlm.nih.gov/pubmed/36747029
http://dx.doi.org/10.1038/s41598-023-29397-z
work_keys_str_mv AT hatananako adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT shigeyasukunitoshi adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT umedayuzo adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT yanoshuya adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT takedasho adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT yoshidakazuhiro adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT fujitomokazu adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT yoshidaryuichi adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT yasuikazuya adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT umedahibiki adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT takahashitoshiaki adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT kondoyoshitaka adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT kishimotohiroyuki adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT moriyoshiko adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT teraishifuminori adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT yamamotohideki adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT michiuehiroyuki adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT nakamurakeiichiro adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT tazawahiroshi adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer
AT fujiwaratoshiyoshi adar1isapromisingriskstratificationbiomarkerofremnantliverrecurrenceafterhepaticmetastasectomyforcolorectalcancer